FDA Adverse Event Injury Summary report: N

VELA XL

MDR report key: 18906175 · Received March 14, 2024

Report

Report Number
2124215-2024-15585
Event Type
Injury
Date Received
March 14, 2024
Date of Event
June 27, 2023
Report Date
June 19, 2024
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
GEX
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ABHAY SETIA, SLOBODAN DIKIC, SAHIT DEMHASAJ, THOMAS SCHMITZ-RIXEN, RONALD SROKA, AND CLAUS-GEORG SCHMEDT. PROSPECTS OF ENDOVENOUS LASER ABLATION (EVLA) STANDARDIZATION-MID-TERM RESULTS OF A FOUR-ZONE DOSIMETRY GUIDING TOOL FOR 1940 NM LASER. J. CLIN. MED. 2023, 12, 4313. HTTPS://DOI.ORG/10.3390/JCM12134313.

Additional Manufacturer Narrative · 0

ABHAY SETIA, SLOBODAN DIKIC, SAHIT DEMHASAJ, THOMAS SCHMITZ-RIXEN, RONALD SROKA, AND CLAUS-GEORG SCHMEDT. PROSPECTS OF ENDOVENOUS LASER ABLATION (EVLA) STANDARDIZATION-MID-TERM RESULTS OF A FOUR-ZONE DOSIMETRY GUIDING TOOL FOR 1940 NM LASER. J. CLIN. MED. 2023, 12, 4313. HTTPS://DOI.ORG/10.3390/JCM12134313.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC VIA AN ARTICLE PUBLISHED IN THE JOURNAL OF CLINICAL MEDICINE THAT A PROSPECTIVE, NON-RANDOMIZED, OBSERVATIONAL STUDY WAS CONDUCTED TO EVALUATE THE EFFICACY OF ENDOVENOUS LASER ABLATION (EVLA) USING A 1940 NM-LASER AND RADIAL-FIBER SUPPORTED BY A FOUR-ZONE DOSIMETRY TOOL. A TOTAL OF 152 CONSECUTIVE PATIENTS FOR THE STUDY WERE RECRUITED BETWEEN 01JUN2017 AND 30JUL2019. ALL PROCEDURES WERE CONDUCTED AT THE SAME HOSPITAL. ALL PATIENTS WERE GREATER THAN 18 YEARS OLD WITH PRIMARY VARICOSE VEINS WITH INCOMPETENT TRUNCAL VEINS WITH AN OUTER DIAMETER (OD) LESS THAN OR EQUAL TO 13 MM. PATIENTS WITH OD GREATER THAN 13 MM WERE ACCEPTED ONLY WHEN THEY HAD SMALL, LOCALIZED DILATATIONS THAT INVOLVED UP TO 3 CM SEGMENTS OF THE TRUNCAL VEIN. THE EVLA PROCEDURES WERE CARRIED OUT USING A THULIUM FIBER LASER SYSTEM EMITTING AT 1940NM, IN COMBINATION WITH A RADIAL EMITTING FIBER SYSTEM. THERE WERE NO INTRAOPERATIVE COMPLICATIONS OBSERVED. FOLLOW-UP EXAMINATIONS WERE PERFORMED WITHIN 1 MONTH, AND AT OR AFTER 12 MONTHS. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, 4 PATIENTS EXPERIENCED LASER-INDUCED PARAESTHESIA IN THE INNERVATION AREAS OF THE SAPHENOUS NERVE BELOW THE KNEE. THIS REGRESSED IN THREE PATIENTS AT 12 MONTHS AND WAS PERSISTENT BELOW THE KNEE IN ONE PATIENT. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, FOUR PATIENTS EXPERIENCED MECHANICALLY INDUCED PARAESTHESIA IN REGIONS OF MINI-PHLEBECTOMY INCISIONS ACCOMPANYING THE EVLA PROCEDURES. THIS WAS PERSISTENT IN ONE PATIENT AT THE 12-MONTH FOLLOW-UP VISIT. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, 10 PATIENTS HAD MECHANICALLY INDUCED HEMATOMAS IN REGIONS OF THE MINI-PHLEBECTOMY INCISIONS. FIVE OF THESE INVOLVED THE THIGH AND 5 INVOLVED THE LOWER LEG. ALL OF THE HEMATOMAS HAD REGRESSED AT THE 12-MONTH FOLLOW-UP VISIT. ENDOVENOUS HEAT-INDUCED THROMBOSIS (EHIT) WAS OBSERVED IN 3 PATIENTS WITHIN ONE MONTH. ALL OF THESE PATIENTS RECEIVED THERAPEUTIC ANTICOAGULATION AND WERE FOLLOWED-UP WEEKLY. EHIT WAS NO LONGER PRESENT AT THE 12-MONTH FOLLOW-UP VISIT. THERE WERE TWO PATIENTS WHO EXPERIENCED EARLY ANATOMICAL FAILURE OF THE EVLA PROCEDURE, WHICH WAS DEFINED AS NON-OCCLUSION. AT THE 12-MONTH FOLLOW-UP VISIT, EIGHT PATIENTS WERE DEVELOPING RECANALIZATION. OVERALL, PATIENTS EXPERIENCED SUCCESSFUL PROCEDURES WITH 98.9% OCCLUSION AT THE 1-MONTH FOLLOW-UP VISIT AND 93.7% OCCLUSION AT THE 12-MONTH FOLLOW-UP VISIT.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC VIA AN ARTICLE PUBLISHED IN THE JOURNAL OF CLINICAL MEDICINE THAT A PROSPECTIVE, NON-RANDOMIZED, OBSERVATIONAL STUDY WAS CONDUCTED TO EVALUATE THE EFFICACY OF ENDOVENOUS LASER ABLATION (EVLA) USING A 1940 NM-LASER AND RADIAL-FIBER SUPPORTED BY A FOUR-ZONE DOSIMETRY TOOL. A TOTAL OF 152 CONSECUTIVE PATIENTS FOR THE STUDY WERE RECRUITED BETWEEN 01JUN2017 AND 30JUL2019. ALL PROCEDURES WERE CONDUCTED AT THE SAME HOSPITAL. ALL PATIENTS WERE GREATER THAN 18 YEARS OLD WITH PRIMARY VARICOSE VEINS WITH INCOMPETENT TRUNCAL VEINS WITH AN OUTER DIAMETER (OD) LESS THAN OR EQUAL TO 13 MM. PATIENTS WITH OD GREATER THAN 13 MM WERE ACCEPTED ONLY WHEN THEY HAD SMALL, LOCALIZED DILATATIONS THAT INVOLVED UP TO 3 CM SEGMENTS OF THE TRUNCAL VEIN. THE EVLA PROCEDURES WERE CARRIED OUT USING A THULIUM FIBER LASER SYSTEM EMITTING AT 1940NM, IN COMBINATION WITH A RADIAL EMITTING FIBER SYSTEM. THERE WERE NO INTRAOPERATIVE COMPLICATIONS OBSERVED. FOLLOW-UP EXAMINATIONS WERE PERFORMED WITHIN 1 MONTH, AND AT OR AFTER 12 MONTHS. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, 4 PATIENTS EXPERIENCED LASER-INDUCED PARAESTHESIA IN THE INNERVATION AREAS OF THE SAPHENOUS NERVE BELOW THE KNEE. THIS REGRESSED IN THREE PATIENTS AT 12 MONTHS AND WAS PERSISTENT BELOW THE KNEE IN ONE PATIENT. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, FOUR PATIENTS EXPERIENCED MECHANICALLY INDUCED PARAESTHESIA IN REGIONS OF MINI-PHLEBECTOMY INCISIONS ACCOMPANYING THE EVLA PROCEDURES. THIS WAS PERSISTENT IN ONE PATIENT AT THE 12-MONTH FOLLOW-UP VISIT. WITHIN THE ONE-MONTH FOLLOW-UP PERIOD, 10 PATIENTS HAD MECHANICALLY INDUCED HEMATOMAS IN REGIONS OF THE MINI-PHLEBECTOMY INCISIONS. FIVE OF THESE INVOLVED THE THIGH AND 5 INVOLVED THE LOWER LEG. ALL OF THE HEMATOMAS HAD REGRESSED AT THE 12-MONTH FOLLOW-UP VISIT. ENDOVENOUS HEAT-INDUCED THROMBOSIS (EHIT) WAS OBSERVED IN 3 PATIENTS WITHIN ONE MONTH. ALL OF THESE PATIENTS RECEIVED THERAPEUTIC ANTICOAGULATION AND WERE FOLLOWED-UP WEEKLY. EHIT WAS NO LONGER PRESENT AT THE 12-MONTH FOLLOW-UP VISIT. THERE WERE TWO PATIENTS WHO EXPERIENCED EARLY ANATOMICAL FAILURE OF THE EVLA PROCEDURE, WHICH WAS DEFINED AS NON-OCCLUSION. AT THE 12-MONTH FOLLOW-UP VISIT, EIGHT PATIENTS WERE DEVELOPING RECANALIZATION. OVERALL, PATIENTS EXPERIENCED SUCCESSFUL PROCEDURES WITH 98.9% OCCLUSION AT THE 1-MONTH FOLLOW-UP VISIT AND 93.7% OCCLUSION AT THE 12-MONTH FOLLOW-UP VISIT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2077367 VELA XL POWERED LASER SURGICAL INSTRUMENT GEX BOSTON SCIENTIFIC CORPORATION UNK-P-VELA_XL_4101_CONSOLE

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention